DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease

Information source: Fred Hutchinson Cancer Research Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Graft Versus Host Disease; Recurrent Adult Acute Lymphoblastic Leukemia

Intervention: prednisone (Drug); methylprednisolone (Drug); questionnaire administration (Other)

Phase: Phase 3

Status: Completed

Sponsored by: Fred Hutchinson Cancer Research Center

Official(s) and/or principal investigator(s):
Marco Mielcarek, Principal Investigator, Affiliation: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Summary

This randomized phase III trial is studying low-dose prednisone or methylprednisolone to see how well they work compared with standard-dose prednisone or methylprednisolone in treating patients with newly diagnosed acute graft-versus-host disease (GVHD). Glucocorticoids, such as prednisone or methylprednisolone at a starting dose of 2 mg/kg/day are standard treatment for acute graft-versus-host disease caused by a donor stem cell transplant. It is not yet known whether low-dose glucocorticoids are more effective than standard-dose glucocorticoids in treating acute graft-versus-host-disease

Clinical Details

Official title: A Phase III Study to Determine Efficacy and Safety of Low-Dose Glucocorticoids for Initial Treatment of Acute Graft-versus-Host Disease

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Primary outcome: Mean Cumulative Prednisone Dose (mg/kg) Over 42 Days From the Start of Treatment

Secondary outcome:

Prednisone-associated Toxicity as Assessed by Hyperglycemia

Prednisone-associated Toxicity as Assessed by Invasive Infections (Bacterial, Fungal and Viral)

Prednisone-associated Toxicity as Assessed by Myopathy

Prednisone-associated Toxicity as Assessed by Hypertension

Prednisone-associated Toxicity as Assessed by Quality of Life

Non-relapse Mortality

Recurrent or Progressive Malignancy

Progression to Grade III-IV Acute GVHD

Secondary Therapy for Acute GVHD Beyond Prednisone

Chronic Extensive GVHD

Overall Survival

Detailed description: OBJECTIVES: I. To determine whether a lower starting dose of prednisone for treatment of newly diagnosed acute GVHD results in decreased prednisone exposure without compromising overall survival. II. To estimate the magnitude of clinical benefit associated with the reduction in prednisone exposure. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I (Low-dose; prednisone-equivalent dose at initiation of treatment of 0. 5 mg/kg/day or 1. 0 mg/kg/day; stratified according to initial symptom severity): Patients receive low-dose prednisone or methylprednisolone once or twice daily in the absence of disease progression or unacceptable toxicity. ARM II (Standard-dose; prednisone-equivalent dose at initiation of treatment of 1. 0 mg/kg/day or 2. 0 mg/kg/day; stratified according to initial symptom severity): Patients receive standard-dose prednisone or methylprednisolone once or twice daily in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 1 year and then annually thereafter.

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients with newly diagnosed acute GVHD (>= grade IIa) for whom, in the judgment of

the attending physician, initial treatment with systemic glucocorticoids is indicated

- Patient or guardian able and willing to provide informed consent

Exclusion Criteria:

- Hallmarks of chronic GVHD

- GVHD after donor lymphocyte infusion (DLI)

- Patient unwilling to remain in Seattle under the care of the Fred Hutchinson Cancer

Research Center (FHCRC)/Seattle Cancer Care Alliance (SCCA) through day 42 after the start of treatment for GVHD

- Uncontrolled infection or other underlying comorbidity (i. e. severe psychiatric

illness) that precludes the use of "standard-dose" prednisone

- Recent diagnosis of recurrent or progressive malignancy that precludes the use of

"standard-dose" prednisone

- Any prior systemic therapy for acute GVHD (Patients may receive up to 2 doses of

low-dose prednisone prior to randomization; low-dose prednisone is defined as 0. 5 mg/kg/dose for patients who present with grade IIa GVHD and 1 mg/kg/dose for those who present with grade IIb-IV GVHD)

- Enrollment on Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) trial

0802

Locations and Contacts

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington 98109, United States
Additional Information

Starting date: June 2009
Last updated: March 3, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017